|
20 Nov 2019 |
Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis
|
|
20 Nov 2019 |
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
|
|
20 Nov 2019 |
Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1
|
|
19 Nov 2019 |
Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
|
|
19 Nov 2019 |
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
|
|
19 Nov 2019 |
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
|
|
19 Nov 2019 |
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
|
|
19 Nov 2019 |
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159
|
|
19 Nov 2019 |
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
|
|
18 Nov 2019 |
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
|
|
18 Nov 2019 |
Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack
|
|
16 Nov 2019 |
CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma
|
|
16 Nov 2019 |
CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
|
|
16 Nov 2019 |
RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
|
|
16 Nov 2019 |
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
|
|
15 Nov 2019 |
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
|
|
14 Nov 2019 |
Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111
|
|
13 Nov 2019 |
Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
|
|
13 Nov 2019 |
Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors
|
|
12 Nov 2019 |
Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting
|
|
12 Nov 2019 |
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
|
|
12 Nov 2019 |
Anifrolumab demonstrated superiority across multiple efficacy endpoints in patients with systemic lupus erythematosus in Phase III TULIP 2 trial
|
|
11 Nov 2019 |
Mereo BioPharma’s Setrusumab Demonstrates Dose-Dependent Bone Building and Trend in Fracture Reduction in Phase 2b ASTEROID Study in Adults with Osteogenesis Imperfecta
|
|
11 Nov 2019 |
Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs
|
|
11 Nov 2019 |
Akesobio Presents Phase 1 Clinical Data from First-in-class Bispecific Drug Candidate AK104 (PD1/CTLA4) As Oral Presentation, at 2019 SITC Annual Meeting
|
